Lunsford L D, Linskey M E
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pennsylvania.
Otolaryngol Clin North Am. 1992 Apr;25(2):471-91.
Stereotactic radiosurgery is performed under local anesthesia, and most patients can be discharged from the hospital within 24 hours of treatment. All patients in our series returned to their preoperative level of employment or function within 5 to 7 days of treatment, and this functional level was maintained over the period of follow-up. "Tumor control" was achieved in 96% of patients during an average follow-up of 1.7 years. Tumor shrinkage occurred in 45% of patients who had at least 1.5 years of follow-up. Useful hearing preservation rates were 50% at 6 months and 30% 1 year after treatment. New delayed facial or trigeminal neuropathy occurred in 34% and 32% of patients, respectively, with a median onset of 5 to 6 months after treatment. The vast majority of cranial neuropathies were partial at onset and tended to improve over time. Other complications included tumor growth (4%), communicating hydrocephalus (4%), and transient adjacent brain parenchymal changes best seen on T2-weighted MRI (9%). Stereotactic radiosurgery is an important alternative treatment for carefully selected patients with acoustic tumors. Indications for treatment include sufficient medical problems to pose excessive surgical risk, advanced age, the presence of bilateral acoustic tumors or contralateral deafness, recurrent tumor despite surgical resection, or refusal to undergo microsurgery. Radiosurgery is contraindicated in patients with symptomatic brain stem or cerebellar compression from a large acoustic tumor. Previous posterior fossa radiotherapy is a relative contraindication that must be considered on a patient to patient basis. Stereotactic radiosurgery should be viewed as an additional weapon in our arsenal for combating acoustic tumors rather than feared as a potential replacement for surgical excision. The strategic role of stereotactic radiosurgery in the overall treatment of patients with acoustic tumors will continue to be refined as longer-term, carefully assessed results become available.
立体定向放射外科手术在局部麻醉下进行,大多数患者在治疗后24小时内即可出院。我们系列研究中的所有患者在治疗后5至7天内恢复到术前的工作或功能水平,并且在随访期间保持这一功能水平。在平均1.7年的随访中,96%的患者实现了“肿瘤控制”。在至少随访1.5年的患者中,45%出现了肿瘤缩小。治疗后6个月有用听力保留率为50%,1年时为30%。分别有34%和32%的患者出现新的迟发性面神经或三叉神经病变,中位发病时间为治疗后5至6个月。绝大多数颅神经病变起病时为部分性,且往往随时间改善。其他并发症包括肿瘤生长(4%)、交通性脑积水(4%)以及在T2加权磁共振成像上最易见的短暂性邻近脑实质改变(9%)。立体定向放射外科手术是精心挑选的听神经瘤患者重要的替代治疗方法。治疗指征包括存在足够多的医疗问题导致手术风险过高、高龄、双侧听神经瘤或对侧耳聋、手术切除后肿瘤复发或拒绝接受显微手术。对于因大型听神经瘤导致有症状的脑干或小脑受压的患者,放射外科手术是禁忌的。既往后颅窝放疗是一项相对禁忌证,必须根据患者个体情况加以考虑。立体定向放射外科手术应被视为我们对抗听神经瘤武器库中的又一利器,而不应被惧怕为手术切除的潜在替代方法。随着更长期、经过仔细评估的结果出现,立体定向放射外科手术在听神经瘤患者整体治疗中的战略作用将不断得到完善。